ClinicalTrials.gg
Active, not recruitingNCT06614192Updated Sep 23, 2026

A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

A Phase 2 interventional study of Telisotuzumab Adizutecan in Metastatic Colorectal Cancer, sponsored by AbbVie. Active, not recruiting at 51 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Colorectal Neoplasms by AbbVie — 4 open to participants now, 8 under way, 1 of them phase 3. Colorectal Neoplasms · AbbVie.

Enrollment
10th of 17
74 · median 101
Started
2024
with 1 other
Phase 2
5 of 17
2 open now
Registered
13th of 17
by date

Among the 17 studies in Colorectal Neoplasms by AbbVie, this one is the 10th largest by enrollment, is one of 2 that started in 2024, is one of 5 in phase 2, and was the 13th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 17 studies in Colorectal Neoplasms by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Colorectal Neoplasms by AbbVie, or all of them as a file.
02

Study summary

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events and change in disease activity of intravenously (IV) infused telisotuzumab adizutecan in adult participants with c-Met protein above cutoff level refractory metastatic colorectal cancer (mCRC).

Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants are put into treatment arms and each treatment arm receives a different dose of telisotuzumab adizutecan. Up to approximately 60 adult participants with c-Met protein above cutoff level refractory mCRC, will be enrolled in the study at approximately 80 sites in 7 countries.

Participants will receive intravenously (IV) infused telisotuzumab adizutecan dose A or B. The total study duration will be approximately 4 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • Metastatic Colorectal Cancer
  • Telisotuzumab Adizutecan
  • ABBV-400
  • AndroMETa-CRC-064
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >= 12 weeks per investigator assessment.
  • (ECOG) performance status (PS) of 0 or 1 during the screening period prior to the first dose of the study drug.
  • per (RECIST), version 1.1.

Exclusion criteria

Exclusion Criteria:

  • Prior systemic regimen containing c-MET targeting antibody/bispecific or Antibody Drug Conjugate (c-Met targeting Antibody Drug Conjugate [ADC]).
  • History of allergic reactions or to bevacizumab or any of its , or to compounds similar to trifluridine/tipiracil.
  • Active infection as noted in the protocol.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Telisotuzumab Adizutecan Dose A

    Participants will receive telisotuzumab adizutecan dose A, as part of the approximately 4 year study duration.

  • Experimental
    Telisotuzumab Adizutecan Dose B

    Participants will receive telisotuzumab adizutecan dose B, as part of the approximately 4 year study duration.

    Drug: Telisotuzumab Adizutecan

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Adverse Events (AE)s

    An AE is defined as any untoward medical occurrence, inappropriate patient management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational drug.

    Time frame: Up to a Maximum of 4 Years

  2. Percentage of Participants with Clinically Significant Vital Sign Measurements as Assessed by the Investigator

    Vital signs are defined as determinations of systolic and diastolic blood pressure, pulse rate, respiratory rate, oxygen saturation (SpO2), and body temperature will be obtained at visits.

    Time frame: Up to a Maximum of 4 Years

  3. Percentage of Participants with Clinically Significant Electrocardiograms (ECGs) Findings as Assessed by the Investigator

    Percentage of participants with clinically significant ECGs findings as assessed by the investigator.

    Time frame: Up to a Maximum of 4 Years

  4. Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, Hematology, Coagulation, and Urinalysis) as Assessed by the Investigator

    Percentage of participants with clinically significant laboratory values (hematology, chemistry, coagulation, and urinalysis) as assessed by the investigator.

    Time frame: Up to a Maximum of 4 Years

  5. Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)

    OR is defined as confirmed complete response (CR) or confirmed partial response (PR) as assessed by BICR per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

    Time frame: Up to a Maximum of 4 Years

  6. Overall Survival (OS)

    OS is defined as the time from randomization to the event of death from any cause.

    Time frame: Up to a Maximum of 4 Years

Secondary outcomes

  1. Progression Free Survival (PFS) as Assessed by BICR

    PFS is defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 as determined by BICR or death from any cause, whichever occurs earlier.

    Time frame: Up to a Maximum of 4 Years

  2. OS

    OS is defined as the time from randomization to the event of death from any cause

    Time frame: Up to a Maximum of 4 Years

  3. Duration of Response (DOR) as Assessed by BICR

    DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 as determined by BICR or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR.

    Time frame: Up to a Maximum of 4 Years

  4. Disease Control (DC) as Assessed by BICR

    DC is defined as best overall response of confirmed CR or confirmed PR, or stable disease (SD) based on RECIST, version 1.1 as determined by BICR.

    Time frame: Up to a Maximum of 4 Years

  5. OR as Assessed by Investigator

    OR is defined as confirmed CR or confirmed PR as assessed by investigator per RECIST, version 1.1.

    Time frame: Up to a Maximum of 4 Years

  6. PFS as Assessed by Investigator

    PFS is defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 as determined by investigator or death from any cause, whichever occurs earlier.

    Time frame: Up to a Maximum of 4 Years

  7. DOR as Assessed by Investigator

    DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 as determined by BICR or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR.

    Time frame: Up to a Maximum of 4 Years

  8. Maximum Observed Serum (or Plasma, for Payload) Concentration (Cmax) for Telisotuzumab Adizutecan

    Maximum observed serum (or plasma, for payload) concentration for telisotuzumab adizutecan.

    Time frame: Up to a Maximum of 4 Years

  9. Time to Cmax (Tmax) for Telisotuzumab Adizutecan

    Time to Cmax for telisotuzumab adizutecan.

    Time frame: Up to a Maximum of 4 Years

  10. Terminal Elimination Half-Life (t1/2) for Telisotuzumab Adizutecan

    Terminal elimination half-life for telisotuzumab adizutecan.

    Time frame: Up to a Maximum of 4 Years

  11. Area Under the Serum (or Plasma, for Payload) Concentration Versus Time Curve (AUC) for Telisotuzumab Adizutecan

    Area under the serum (or plasma, for payload) concentration versus time curve will be determined using noncompartmental methods for total antibody for telisotuzumab adizutecan.

    Time frame: Up to a Maximum of 4 Years

  12. Antibody Drug Conjugate (ADC) for Telisotuzumab Adizutecan

    Antibody drug conjugate for telisotuzumab adizutecan.

    Time frame: Up to a Maximum of 4 Years

  13. Unconjugated Topoisomerase 1 (Top1) Inhibitor Payload for Telisotuzumab Adizutecan

    Unconjugated Top1 inhibitor payload for telisotuzumab adizutecan.

    Time frame: Up to a Maximum of 4 Years

  14. Incidence of Anti-Drug Antibodies (ADAs) for Telisotuzumab Adizutecan

    Incidence of anti-drug antibodies for telisotuzumab adizutecan.

    Time frame: Up to a Maximum of 4 Years

  15. Neutralizing Anti-Drug Antibodies (nADAs) for Telisotuzumab Adizutecan

    Neutralizing anti-drug antibodies for telisotuzumab adizutecan.

    Time frame: Up to a Maximum of 4 Years

07

Study locations

51 sites
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Aug 2027, 33 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 33 months is close to that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2024
First posted
Sep 26, 2024
StartActual
Nov 8, 2024
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06614192
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 26, 2024
Start date
Nov 8, 2024
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 23, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telisotuzumab adizutecan

Start the discussion